DTU
DTU

Professor Rury Holman

Picture of Rury Holman Highly Cited Researcher

Position:Director

PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240

Email:rury.holman@dtu.ox.ac.uk

ORCID ID0000-0002-1256-874X

Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 325 peer-reviewed papers that have been cited more than 55,000 times.

Latest publications

Manuscript
An Outcome Model Approach to Generalizing Randomized Controlled Trial Results to a Target Population
Benjamin A. Goldstein et al.
J Am Med Inform Assoc. 2019;5:429–437

Manuscript

M. Angelyn Bethel et al.
Diabetes Care 2019

Manuscript
Comparison of Nine Platelet Function Tests Used to Determine Responses to Different Aspirin Dosages in People with Type 2 Diabetes
Paul Harrison et al.
Platelets 2019;30:521-529

Manuscript
Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017
John M Dennis et al.
Diabetes Obes Metab 2019

Manuscript
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9,259 Deaths in 9 Trials
Alexander C Fanaroff et al.
Circulation 2019;139:863-873

Manuscript
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Lindsay E. Clegg et al.
Diabetes Care 2019;42:318-326